Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Kidney Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

belzutifan 7Nivolumab 7pembrolizumab 6Ipilimumab 5Surveys and Questionnaires 3lenvatinib 2cabozantinib 2Radiosurgery 2Paclitaxel 2Everolimus 2Carboplatin 2pazopanib 1palbociclib 1liposomal doxorubicin 1guadecitabine 1fludarabine phosphate 1endothelial PAS domain-containing protein 1 1durvalumab 1cemiplimab 1atezolizumab 1aldesleukin 1X-Rays 1Technetium Tc 99m Sestamibi 1Taxes 1Sunitinib 1Spermine Synthase 1Social Determinants of Health 1Single Photon Emission Computed Tomography Computed Tomography 1Radiotherapy 1Radionuclide Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Kidney Neoplasms × guadecitabine × Clear all
NCT03308396 2022-02-17

Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

Big Ten Cancer Research Consortium

Phase 1/2 Active not recruiting
57 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡